1-4 of 4
Minh Nguyen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM-Deficient Tumors and Potent Synergy With PARP Inhibitors

Available to Purchase
Anish Thomas, Shaun D. Fontaine, Morgan E. Diolaiti, Parth Desai, Rajesh Kumar, Nobuyuki Takahashi, Linda Sciuto, Samantha Nichols, Alan Ashworth, Felix Y. Feng, Gary W. Ashley, Minh Nguyen, Yves Pommier, Daniel V. Santi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (11): 1722–1728.
https://doi.org/10.1158/1535-7163.MCT-22-0217
Published: 03 November 2022
View articletitled, PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM-Deficient Tumors and Potent Synergy With PARP Inhibitors
Open the PDF for PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM-Deficient Tumors and Potent Synergy With PARP Inhibitors in another window
Includes: Supplementary data
Journal Articles

Abstract LBA032: Pan-cancer analysis of fibroblast activation protein alpha (FAP) expression to guide tumor selection for the peptide-targeted radionuclide therapy FAP-2286

Free
Tanya T. Kwan, Minh Nguyen, Dirk Zboralski, Anne Schumann, Anne Bredenbeck, Matthias Paschke, Christian Haase, Aileen Hoehne, Ulrich Reineke, Christiane Smerling, Frank Osterkamp, Jim Xiao, Andrew D. Simmons, Thomas C. Harding, Kevin L. Lin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): LBA032.
https://doi.org/10.1158/1535-7163.TARG-21-LBA032
Published: 01 December 2021
View articletitled, Abstract LBA032: Pan-cancer analysis of fibroblast activation protein alpha (FAP) expression to guide tumor selection for the peptide-targeted radionuclide therapy FAP-2286
Journal Articles

Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor

Free
Remi Adelaiye-Ogala, Berkley E. Gryder, Yen Thi Minh Nguyen, Aian Neil Alilin, Adlai R. Grayson, Wardah Bajwa, Keith H. Jansson, Michael L. Beshiri, Supreet Agarwal, Jose Antonio Rodriguez-Nieves, Brian Capaldo, Kathleen Kelly, David J. VanderWeele
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2020) 19 (7): 1436–1447.
https://doi.org/10.1158/1535-7163.MCT-19-0936
Published: 02 July 2020
View articletitled, Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor
Open the PDF for Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor in another window
Includes: Supplementary data
Journal Articles

Abstract C199: PI3K/AKT/mTOR inhibitors enhance the anti-tumor activity of the FGFR, VEGFR and PDGFR inhibitor lucitanib in FGF-dependent breast cancer models

Free
Minh Nguyen, Liliane Robillard, Andrew D. Simmons, Henry J. Haringsma, Thomas C. Harding
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C199.
https://doi.org/10.1158/1535-7163.TARG-15-C199
Published: 01 December 2015
View articletitled, Abstract C199: PI3K/AKT/mTOR inhibitors enhance the anti-tumor activity of the FGFR, VEGFR and PDGFR inhibitor lucitanib in FGF-dependent breast cancer models